Previous 10 | Next 10 |
2024-03-20 13:10:49 ET Summary Gilead Sciences has seen weak price momentum over the past year following the sales drop in its COVID-19 medication Veklury, even as sales-ex Veklury look alright and earnings have grown. The company has a relatively positive revenue and earnings gui...
NORTHAMPTON, MA / ACCESSWIRE / March 19, 2024 / Gilead Sciences: In the summer of 2019, Bora was celebrating his mother's birthday at a seaside restaurant in Istanbul when he suddenly became very ill and couldn't finish his meal. "I woke up the next day with a high fever and terrible pain and ...
2024-03-19 07:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the United States back to care. The program is funded by an eight-million-dollar grant from Gilead Sciences ...
2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...
2024-03-17 08:15:00 ET Finding high-yielding companies isn't everything when investing in dividend stocks. Sometimes, companies' yields increase after their share prices drop significantly, which can occasionally be a sign that the business could be in trouble and may have to decrease its p...
2024-03-16 12:57:30 ET More on Madrigal Pharmaceuticals Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Ra...
2024-03-13 15:52:06 ET Gilead Sciences, Inc. (GILD) Barclays 26th Annual Global Healthcare Conference March 13, 2024 11:15 AM ET Company Participants Andy Dickinson - CFO Conference Call Participants Carter Gould - Barclays Presentation Carter G...
2024-03-13 08:10:58 ET Summary US stocks climbed higher in February with the DJIA adding 0.4% and the S&P closing in on the 5,000-point mark. Interest rates were kept steady again in a range of 5.25% to 5.5%, with the market now projecting fewer hikes this year as the economy ...
2024-03-12 20:26:02 ET Gilead Sciences, Inc. (GILD) Leerink Partners Global Biopharma Conference March 12, 2024 10:00 AM ET Company Participants Cindy Perettie - EVP, Kite Conference Call Participants Daina Graybosch - Leerink Partners Presentation ...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...